Third Wave Countersues Digene for 'Monopolistic Abuse' in HPV Dx Market | GenomeWeb
NEW YORK (GenomeWeb News) — Third Wave Technologies today said it has countersued Digene after the company sued Third Wave in January for allegedly infringing its human papillomavirus IP.
 
In its suit, filed with the US District Court for the Western District of Wisconsin, Third Wave claims Digene has “abused its monopoly power to thwart competition” in the HPV diagnostics market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.